Sammanfattning
Patients with Type 2 diabetes have an increased risk of cardiovascular disease. However, there exists a considerable heterogeneity in cardiovascular risk in this patient population. A heterogeneity, which may escape the predictive capability of established clinical risk scores. In this context, cardiovascular biomarkers are of significant interest as potential clinical tools to guide risk stratification of patients. Studies have identified N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T of particular potential in patients with Type 2 diabetes.